Status
Conditions
About
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Full description
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Alexion Pharmaceuticals, Inc. (Sponsor)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal